Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors

Journal Publication ResearchOnline@JCU
Han, Shuanglin;Latchoumanin, Olivier;Wu, Guang;Zhou, Gang;Hebbard, Lionel;George, Jacob;Qiao, Liang
Abstract

Chimeric antigen receptors (CARs) are a series of manufactured receptors that have the capacity of binding to specific antigens expressed on surface of tumor cells. A CAR normally has an extracellular antigen recognition domain derived from single variable chain of a monoclonal antibody, a transmembrane domain and an intracellular T cell activation domain. During the last decade, CAR-T cells were demonstrated to possess great therapeutic effects on hematological malignancies. However, strategies using CAR-T cells to treat solid tumors have been hindered by considerable obstacles including "on tissue off target" effects and cytokine storm syndrome. This review will summarize the current understanding of CAR-T cell therapies and briefly describe the currently enrolled clinical trials in solid tumors.

Journal

Cancer Letters

Publication Name

N/A

Volume

390

ISBN/ISSN

1872-7980

Edition

N/A

Issue

N/A

Pages Count

13

Location

N/A

Publisher

Elsevier

Publisher Url

N/A

Publisher Location

N/A

Publish Date

N/A

Url

N/A

Date

N/A

EISSN

N/A

DOI

10.1016/j.canlet.2016.12.037